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Introduction
Irritable bowel syndrome (IBS) is a multi-faceted disease 
characterized by bowel instability, bloating and abdominal 
pain (1). It is a common diagnosis, with an estimated 
prevalence of up to 20% in the western world (2). There is 
no clear pathogenesis for IBS and diagnosis is made based 
on the exclusion of an organic cause (1). Varying subtypes 
of IBS have been described based on the predominance 
of constipation, diarrhea or a mixed presentation (1). The 
gastrointestinal symptoms of IBS significantly impact 
everyday functioning, with some reports indicating that it 
is the second-leading cause of workplace absenteeism in 
the United States (3). It is also a leading cause of referral to 
gastroenterology (4). 
As the pathophysiology of IBS is not well understood, 
multiple theories have been established (5). Visceral 
hypersensitivity, alterations in fecal microflora, intestinal 
inflammation and psychogenic illness are just some of 
the mechanisms that have been proposed (5). Strong 
associations between IBS and anxiety disorders exist (2). 
Psychosocial markers of anxiety and insomnia are 
independent risk factors for the development of IBS 
symptoms (6). Recently, research has indicated that the 
enteric nervous system may play a role in the pathobiology 
of IBS (6,7). For example, IBS secondary to somatization 
has been well-described (6). Further support for a role of 
the enteric nervous system stems from reports of diabetic 
neuropathy relating to gastroparesis and IBS symptoms. 
In diabetes mellitus, autonomic dysfunction of the enteric 
nervous system can lead to disordered motility and osmotic 
diarrhea (8). 
The bowel is a complex muscular structure essential for 
water reabsorption, nutrient absorption and excretion of 
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waste. Proper functioning of the bowel is dependent on 
peristalsis, which propels faeces towards the rectum. The 
microenvironment of the bowel is tightly controlled and 
can easily be disrupted by changes in neurotransmitters, 
motility, ion balance and to the intestinal microbiome (1). 
Mechanical support is provided by the mesentery, 
which suspends the bowel, facilitating nerve, blood and 
lymphatic supply (9). Our understanding of the bowel 
has been redefined due to current research regarding the 
mesentery (9). The function of the mesentery in bowel 
pathology is a novel area of interest and has potential as a 
pharmacological target (10).
There is a scarcity of research describing IBS secondary 
to peripheral nerve dysfunction outside of the diabetic 
population. This report outlines the case of a non-diabetic 
patient with IBS refractory to traditional therapies. IBS 
symptoms were effectively managed by targeting and 
restoring peripheral nerve imbalance. We present the 
following case in accordance with the CARE reporting 
checklist available at http://dx.doi.org/10.21037/map-19-228.
Case presentation
This case study presents a 66-year-old Caucasian woman 
who presented with persistent and severe diarrhoea. 
For two-and-a-half  years  she experienced severe 
bowel dysmotility and nausea. Bowel movements were 
accompanied by daily abdominal pain and were a cause of 
severe functional impairment. Additionally, she experienced 
significant weight loss during this period. On examination, 
she was found to have peripheral neuropathy. 
Significant negative findings included lack of constipation, 
indigestion and flatulence. Her bowel symptoms were 
refractory to typical therapeutic management including 
d iphenoxy la te  and  domper idone .  Co lonoscop ic 
investigations were unremarkable. Her thyroid function 
demonstrated a normal TSH with a high T4 at 26 μg/dL. 
Exocrine pancreatic dysfunction, carcinoid tumour and 
pheochromocytoma were ruled out by 24-hour urine 
collection and computerized abdominal tomography (CT). 
The patient had a relatively healthy lifestyle. She was 
physically active; either cycling or walking most days and 
did not smoke. She consumed a single unit of alcohol 
per week. Her diet was moderate with good variety and 
avoidance of red meat, sugar and butter. However, she 
reported a poor sleep pattern, averaging five hours per 
night. She also reported feelings of exhaustion and anxiety.
Following consultation, she was started on a range of 
medications aimed at relieving her bowel symptoms. When 
these failed to lead to an improvement in symptoms she was 
commence on the following regimen; Amitriptyline 10 mg, 
nocte; Duloxetine 30 mg, mane; Methimazole 5 mg, od; and 
Pancrelipase 10,000 units, tds. 
This patient returned after 3 months for a follow-
up appointment, at which time her bowel symptoms had 
settled. She reported complete cessation of any diarrhoea 
and abdominal pain. The above described treatment 
regimen was continued. 
Written informed consent was obtained from the patient 
for publication of this case report. All the data for this paper 
had informed consent from the patient involved.
Discussion
This report describes a patient with neuropathic IBS 
experiencing persistent bowel dysfunction. Her symptoms 
were resistant to first-line IBS treatments including dietary 
changes and pharmaceutical management. Her symptoms 
responded extremely well to a second-line regimen 
consisting of low dose Amitriptyline and duloxetine. 
Serotonin (5-HT) is a key mediator of the brain-gut 
relationship. It is secreted by Enterochromaffin (EC) cells 
of the bowel in response to enteric nerve stimulation (11). 
Intestinal microbes influence the production of serotonin 
from EC cells, with reports stating that 90% of serotonin 
production in the body is  mediated by these gut 
microbes (12). Serotonin also plays a large role in the 
control of the mesentery, with 2% of the mesenteric 
neurons consisting of serotonergic neurons (13). Proper 
functioning of the mesentery is required as it plays an 
important role in the support and innervation of the gut, 
thus impacting gut motility. This relationship makes gut 
serotonin balance and the mesentery potential targets to 
regulate bowel function among IBS patients (13).
Restoration of the gut microbiome is one possible 
treatment option for those with IBS. This would include 
dietary changes that promote healthy microbiota (11). 
Improvement of the gut microenvironment impacts the EC 
cell interface which regulates mesenteric serotonin levels 
and impacts control of bowel motility. In some individuals, 
dietary changes alone may not be sufficient to restore 
serotonin balance in the gut (11). For these individuals, 
pharmaceutical intervention is warranted. Medications 
that target serotonin reuptake at the post-synaptic cleft 
have been used to restore this serotonin imbalance. These 
medications include low dose tricyclic antidepressants 
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(TCAs) and low dose serotonin-norepinephrine reuptake 
Inhibitors (SNRIs). The mechanism by which these 
medications improve IBS symptoms is through restoration 
of circadian rhythm to neurons in the mesentery and bowel, 
which help improve peristaltic function (11). TCAs have 
been demonstrated to be effective for the treatment of IBS, 
there is less research supporting the use of SNRIs (14,15).
Peripheral nerve dysfunction is a known complication 
of poorly controlled diabetes. Common sites of peripheral 
neuropathy in these patients are vagal and sympathetic 
nerve dysfunction (16). Diabetic gastroenteropathy typically 
takes the form of gastroparesis, but IBS has also been 
described (16). The cause of the peripheral nerve 
dysfunction in diabetes endocrine dysfunction (i.e., where 
the bowel loses its normal peristaltic rhythm), is still 
unknown (9,16). Novel research postulates disruption of 
the cells of Cajal, found in the intestinal wall, as a possible 
mechanism for diabetic enteropathy (9). Endocrinologists 
have targeted peripheral neuropathy in diabetic patients 
with IBS through the use of low dose TCAs and low dose 
gabapentin with promising results. Less research is available 
on peripheral neuropathy in non-diabetic populations.
This case further supports the link between IBS and 
peripheral nerve dysfunction. The use of anti-depressant 
agents to regulate gut serotonin levels and control bowel 
functioning may be effective in this subset of IBS patients. 
Further research is needed to establish an optimal treatment 
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